Desenvolvimento e análise do efeito de um extrato combinado de andiroba, copaíba e guaraná em modelos de cicatrização in vitro e in vivo

Abstract

BACKGROUND: The skin is the largest organ of the human body and its functions are to coat, delimit, protect and interact with the external environment. Thus, skin healing is a fundamental element for human health, both in the occurrence of injuries and in surgical procedures. The effectiveness of the healing process can be further enhanced through the development of products that originate from plants with traditional use, this importance is enhanced when we consider that p Brazil is a megadiverse country, being the Amazon region the great granary of this diversity. Thus, in this study we sought to develop a healing compound based on andiroba (Carapa guianensis), copaíba (Copaifera langsdorffii) and Guarana (Paullinia Cupana) oils, three plants of Amazonian origin that have potential healing effect via phase modulation inflammatory and proliferative fibroblasts. It is possible that the combination of oils and guarana will result in a potential innovative pharmacological product with high pro-healing potential. OBJECTIVES: General: Develop and analyze the effect of a product obtained via combined extraction of andiroba, copaiba and guarana (ACG) in the form of biphasic oil and emulsion through the analysis of in vitro and in vivo healing models. Specific: Perform the analysis using dermal fibroblasts and Californian worm Eisenia fetida, in vivo model of body regeneration via surgical incision of the caudal region. METHOD: Because it is a study that does not involve direct contact with vertebrates, there is no need for approval by the Ethics Committee. After obtaining the ACG the antioxidant and genotoxic / genoprotective capacity was evaluated in non-cellular tests. For the tests using the commercially derived dermal fibroblast line HFF-1 and Californian worms (Eisenia Fetida), also commercially obtained. The cells were cultured under standard conditions, and in these strach assay (in vitro skin lesion model) tests were performed. The cells were treated with ACG at different concentrations and after 24/72 hour inclination, viability tests / cell proliferation. Growth markers, oxidative stress and inflammation were analyzed. In the in vivo model, the animals had a caudal incision were immediately treated with ACG in the form of oil and emulsion, after 24 hours gene expression was analyzed and after 7 days regeneration patterns were analyzed. Statistical analysis was performed by one-way analysis of variance followed by Tukey post hoc test. Considering significant tests with p <0.05. RESULTS: As a result of the study, ACG demonstrated strong antioxidant activity, and was not genotoxic in the tests performed here. In front of the cellular models presented antioxidant action, anti-inflammatory and pro-cicatricial. In in vivo tests it was able to positively modulate the SOX-4 gene totally related to the regeneration / healing process, even in the presence of ACG oil the regeneration process was more intense even with better angiogenesis. CONCLUSIONS: Thus, despite the methodological limitations, we consider the data obtained in this study to be relevant since a new product called ACG was developed here, whose initial results show antioxidant action, anti-inflammatory and pro-healing of the developed compound, more studies need to be performed. To prove the results obtained here, however, we believe that in the future the development of a commercial product for clinical